Publications by authors named "S Lax"
Incorporation of pathological and (not mandatory) molecular features into the new FIGO 2023 staging system has generated some controversy. Several validations have been published recently that demonstrated the higher prognostic precision of FIGO 2023 compared to the previous FIGO 2009 scheme. In the present article, the authors want to respond to some concerns that were raised by some pathologists and clinicians.
View Article and Find Full Text PDFObjectives: To comprehensively review systematic reviews of prevalence, incidence, and mortality of Raynaud's, Sjögren's and Scleroderma, and to identify any research gaps.
Methods: An umbrella review of English language systematic reviews was undertaken using PubMed and Embase (OVID) covering the period 2000-2023 (PROSPERO CRD42023434865). The estimate and its corresponding 95% confidence interval were reported when available from each systematic review.
Background: Pre-clinical studies suggest AZD1775, a WEE1 kinase inhibitor, potentiates the activity of various chemotherapeutic agents.
Methods: WISTERIA was a prospective, parallel two-group, open-label, dose-finding, phase I clinical trial. Eligible patients had histologically confirmed oral, laryngeal, or hypopharyngeal squamous cell carcinoma, ECOG performance status 0/1, and aged ≥18-to-≤70 years.
Article Synopsis
- Eczema is a major global skin condition that is often treated with topical anti-inflammatory treatments, but there is uncertainty about their effectiveness and safety.* -
- A network meta-analysis was conducted to compare various topical treatments based on data from 291 trials involving over 45,000 participants, primarily from high-income countries.* -
- The analysis found that potent topical steroids and tacrolimus 0.1% were among the most effective treatments; however, many trials exhibited high risk of bias, particularly concerning selective reporting.*